Member Info for chester18

I've just spent the last hour or so reading various reports (both in the US and UK) of the TRX cyber attack.

What I don't understand is why pick Tissue Regenix's San Antonio factory. What would they glean from gathering data about the company.

The process is patented so any copy cat manufacturing can be legally challenged.

If they want to know about current finances then read the latest RNS.

Do they want to know about the current deals, well they have all been announced.

So why, what purpose does it serve?

Chester.

Just to prove that I mean what I say I've just bought 300k at 1.042p and will buy more if and when I have the funds .

Chester.

Morning Stu

I could not agree more. I've been interested and invested in Trx for about 5/6 years and have seen the rapid growth the company has achieved and the takeover of CellRight.

The board have long term plans which will not be hindered by the current set backs.
To be honest I did not think we would ever revisit the 1p a share range so I am very content buying up some more to add to my tally.

As I've said already I'm treating this share as a five year bond. Once over these blips and with the second manufacturing facility up to speed Trx can starting hitting around £20 to £30 million turnover the profits generated will self fund all other growth needs.

Chester.

Morning C7

Glad to hear your news this morning and your trip to Naples.

My best regards

Chester.

On the 15th January I posted:

"Also we don't know how close they are in discussions with potential partners it's all guess work at the moment"

Does the fact that Verona are presenting at the LSX mean they are definitely still looking for a partner or am I reading to much into the fact that they are there ?

Chester.

Given all the background knowledge gained by following this board, especially the satellite images put together by PG we know that Newcrests update is going to lead to a much larger ore body estimate.

So Mr Golddusts messages are a conserted effort indeed a deliberate double bluff to scare off those without the knowledge shared here for the past 12 months.

The games played on Aim are golddust.....lol

Chester.

Hi B2H

It does happen but I'm just sick of the doomongers and their "we're going to hell in a handbag" .....

If MidCap don't play ball then what is the difference if we get an opportunity to put our actual cash into the company. What TRX need is bigger, better, faster processing facilities so they can keep up with the growing clamour for their unique regenerative tissue products.

This is my five year bond... the yield could be pretty good.

Chester.

But what if it was successful at over 2p .......

The current institutional investors may feel that 2.2p a share is fair value and puts cash into the company at confidence inspiring price.

Let's just see how it pans out....

Chester.

Here's an interesting question.....

And what if the 'Placing' is at 2.2p what then.........??

Chester.

I couldn't help myself and just bought a cheeky 60,000 at 1.199p .

Holding long ..... going to be an interesting year for TRX.
I look at it this way, in 2019 they held on to the huge growth of 2018 and although things have been problematic they were still able to grow by 12%. That's not a bad result.

Chester.

My attempts to actually talk about the companys science has yet again ended with trash talking and seeing who can **** who off the best.

I think I will withdraw from this board as I said I would because there is not much to interest anyone who looked in to see what Scancell might be about.

It's getting worse.

So if by raising £5m they go on to triple the business turnover to £40m pa inside two of three years and are able to keep thier average margin around the 50% mark, they would then be creating extra profit revenues of £15 million per annum.

What keeps being deliberately overlooked to fit the doom mongers rhetoric is this is a company with an FDA approved product that has grown the business from £0 to £13m inside 5 years with solid profit figures.
The breakeven turnover when everything is produced in house is around £20m.
That is so achievable once the manufacturing capacity has been sorted and they can increase the number of donors in the US.

Can't happen in five minutes and can't happen without cash injections until they turn that breakeven corner.

Chester.

So if they do come to the market to raise £5million, so what.

As long as that money goes into buying state of the art labs, training, marketing and greater processing all their doing is upping the revenues.

We have until March to when they will either continue with MidCap, have found a new backer or do a fund raise. The share price can be a lot stronger by then if they are able to RNS some good sales figures or left field news. If it goes that way I hope they will let us pi's buy some. Best way to have more shares with the cash going straight to the company.

I'm I for the long haul so don't mind holding the shares I already have and taking more at a placing. Happy with a five year hold.

Chester.

Originally posted 19 Jan 2020 17:45

Here's a question that will help focus your attention on why 1.5p a share is the bargain of a lifetime.
Let's presume there is a fire sale:

What would the various parts of TRX go for?

A) DemaPure, an FDA approved, clinically proven to be safe, cost effective and clinically desired regenerative tissue product.
What is the value of IP, the Patents, the processing plant processing IP and the current growing customer base.
What shall we put £20M, £30M? It's got to be up there in the tens of millions.
B) The heart valve replacement, GMB V joint venture in Germany / Europe. £2M min.
C) SurgiPure XD, FDA approved, proven to be safe just as DermaPure and again all the IP, Patents and customer base. £10M / £15M
D) OrthoPure XT once approved £10m min.
E) Then add all the CellRight BioRinse tech, IP, Patents and signed up contacts. TRX paid £26M in 2017 so let's just say that three years later it's still only worth what was paid.

So even if the rug was pulled from under us the piece parts of the TRX group has to be in excess of £70 / £80Million.

In other words 6p a share, so any and I mean any, good news about production, current level of sales, new contracts, new finance agreement means that 6p has to be the first re-rate position.

This is why the share is a tremendous opportunity and investment.

All my own opinion but I've tried to keep the values sensible. Any comments and other opinions are most welcome.

Chester.

Thanks Ray

If we did agree a territory deal are you saying that we, for instance, give a China Pharma co the sole rights to that technology covering Tag Mabs only.

This is something I don't fully understand.
Are you saying there are different levels of AvidiMab or different slices of the potential market.

Chester.

Thanks Applegarth

Our posts crossed..

Chester

Thanks JerseyCrew

My post was a badly crafted, the main point or question should have been :

"What realistically are we expecting from next weeks Newcrest update other than core results?"

Chester.

Given that the last three or four big news days have resulted in the SP retreating by 20% or so. What realistically are we expecting from next weeks Newcrest update other than core results.

My concern is that the announcement of the 10 to 15 cores we are waiting on may already have been priced in by the 10% traders and sell on news brigade and their plan is to just sell whatever.

Am I better topping up now or waiting until after next weeks news?
This is a genuine concern and would appreciate sensible constructive comments.

Chester.

Passage from Scancells website about AvidiMab.

"Scancell has now patent protected a technology platform (AvidiMab™) which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification reinstates the direct tumour cell killing ability of the anti-glycan humanised mAbs but could also be used to increase the potency of any human mAb and is available for licensing.

Chester.

Morning All

When we have discussed the potential of AvidiMab in the past I thought that any company currently possessing an antibody drug could use AvidiMab to increase its potency and even use it to upgrade their patents.

So I'm thinking just how many Pharma co's are out there that could benefit, tongue in cheek I said 10 to 20 deals would be nice.

But then there was a comment about doing territorial deals, how would that work for Scancell ?

Or have I misconstrued what was being put forward.

Chester.